Company / R&D per Share
BioMarin Pharmaceutical R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$4.79
FY2025
5-year range
$3.46 / $4.79
FY2021-FY2025
Trend
+22.4%
vs FY2024
Sector context
#37 of 208
Health Care
What the data says
BioMarin Pharmaceutical's r&d per share of $4.79 is higher than 82% of companies in the Health Care sector (FY2025). R&D per Share has fluctuated over the past 10 years, ranging from $3.46 in FY2020 to $4.79 in FY2025.
Based on SEC 10-K filings.
4.79 in FY2025 with a 5-year CAGR of +6.8%. Top quartile in the Health Care sector.
Improved from $3.96 to $4.79 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +11.2%
- 5-Year CAGR
- +6.8%
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 208This company $4.79 Sector average $28.82
▼
-83.4% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 22.4% year-over-year.
- Ranks #37 out of 208 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.79 | +22.4% |
| FY2024 | $3.92 | -1.1% |
| FY2023 | $3.96 | +13.5% |
| FY2022 | $3.49 | +0.8% |
| FY2021 | $3.46 | +0.1% |
| FY2020 | $3.46 | -13.1% |
| FY2019 | $3.98 | +1.8% |
| FY2018 | $3.91 | +12.5% |
| FY2017 | $3.47 | -9.4% |
| FY2016 | $3.83 | -2.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026